Signature Diagnostics Overview

  • Founded
  • 2004
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $31.9M
Latest Deal Amount

Signature Diagnostics General Information

Description

Provider of development and commercialization of molecular oncology diagnostic products for early detection and prognosis of cancer. The company has completed development of its first two diagnostic products for colorectal cancer screening ("Detector C/C+") and prognosis ("Predictor C"), which will be launched in 2012 in its own ISO 15189 certified service laboratory. Using its technologies in tissue and blood sample collection, molecular pathology, Xenopatient™ platform, genome-wide profiling, data mining, and biostatistics, the company collaborates with clinical, pharmaceutical, and diagnostic partners. The company sponsors and conducts large prospective, multicenter clinical trials with more than 33 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers in oncology.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Acquirer
Primary Office
  • Hermannswerder 20 A
  • 14473 Potsdam
  • Germany
+49 0331 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Signature Diagnostics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 12-Feb-2015 $31.9M 00.000 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 12-Aug-2008 00.000 00.000 Completed Generating Revenue
3. Early Stage VC (Series B) 30-Jan-2008 Completed Generating Revenue
2. Grant 20-Jun-2005 $1.35M Completed Generating Revenue
1. Early Stage VC 22-Apr-2005 Completed Generating Revenue
To view Signature Diagnostics’s complete valuation and funding history, request access »

Signature Diagnostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of development and commercialization of molecular oncology diagnostic products for early detection and prognosi
Biotechnology
Potsdam, Germany
00.000
00.00 0000-00-00
000000&0 00.000

00000000

is aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
000000000000000
Ladenburg, Germany
00 As of 0000
00000
0000

0000000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Barcelona, Spain
00 As of 0000
000.00
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Signature Diagnostics Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Heidelberg Pharma Formerly VC-backed Ladenburg, Germany 00 00000 0000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 000.00 000000000000 000.00
You’re viewing 2 of 2 competitors. Get the full list »

Signature Diagnostics Executive Team (3)

Name Title Board Seat Contact Info
Hans-Peter Adams Head, Biostatistics & Clinical Trials
André Rosenthal Chief Executive Officer
You’re viewing 2 of 3 executive team members. Get the full list »

Signature Diagnostics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Brandenburg Kapital Venture Capital Minority 000 0000 000000 0
Co-Investor Partners Growth/Expansion Minority 000 0000 000000 0
EVP Capital Management Growth/Expansion Minority 000 0000 000000 0
IBG Beteiligungsgesellschaft Sachsen-Anhalt Venture Capital Minority 000 0000 000000 0
KfW IPEX-Bank Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »